4 Reasons to Buy Medtronic Stock Like There's No Tomorrow

Pulnovo Medical, a Medtronic subsidiary, reported positive results from its PADN-HF-PH trial in PH-LHD patients, showing a 51% reduction in clinical worsening risk and improved functional capacity. The trial was presented at the ESC Congress 2026 and published in NEJM. PADN has received regulatory approvals in 12 countries and is being expanded to treat WHO Group 2 pulmonary hypertension. Medtronic's stock is currently trading at EUR 79.22, down 2.77%.

Medtronic reported Q1 2027 organic revenue growth of 13.7%, driven by strong demand in CRM, CST, and Surgical. Cardiac Ablation Solutions grew 88%, and the company raised FY27 guidance to 7.25%-7.75%. Medtronic plans to separate its Diabetes business and invest in high-growth areas like robotics and neurovascular navigation. Foreign exchange is expected to be a $50M-$150M headwind.

Medtronic (MDT) reported Q1 FY2027 with adjusted operating earnings up 14.9%, adjusted EPS up 15.1%, and free cash flow more than doubling. The company raised revenue and EPS guidance, exceeding consensus. Analysts responded positively, with a consensus Moderate Buy rating and price targets suggesting 10-30% upside. MDT's stock rose 5% premarket. Risks include cybersecurity concerns from a recent breach.

Medtronic (MDT) announced CMS granted a New Technology Add-on Payment (NTAP) for its INFUSE™ Bone Graft for TLIF, effective October 1, 2026. NTAP provides additional reimbursement for hospitals using new technologies, supporting adoption and patient access. INFUSE™ is the first and only growth factor technology approved for spine fusion procedures, receiving FDA approval earlier this year. This milestone highlights Medtronic's commitment to advancing healthcare innovation and expanding access to

Mizuho raised its price target for Medtronic (MDT) to $115 from $100, citing strong growth in cardiovascular products. MDT reported Q1 FY2027 revenue of $9.76B, beating estimates. Multiple analysts raised their price targets, with some noting strong product cycles. MDT's stock trades at $92.38, with a P/E ratio of 22.89.

Deutsche Bank raised its price target for Medtronic to $92 from $78, citing the company's fiscal 2027 performance and growth acceleration. Medtronic's stock is currently trading at $93.12, up 1.18% on the day and 1.37% over the past year.